GIST panel detects more gene mutations

Because multiple genetic mutations are known to cause gastrointestinal stromal tumors (GIST), enhanced testing protocols are needed to confirm the diagnosis.

The MayoComplete Gastrointestinal Stromal Tumor (GIST) Panel, Next-Generation Sequencing, Tumor (Mayo ID: MCGST) evaluates for somatic mutations in solid tumor samples and determines microsatellite instability to confirm a diagnosis of GIST in patients who present with unusual lesions in the GI tract.

“This expanded panel is more sensitive for the diagnosis of GIST,” says Rondell Graham, M.B.B.S. “It covers not only the most commonly mutated genes but also the less commonly mutated genes and GIST mutations that pursue an aggressive disease course.”

To learn more, check out this test-specific episode of the “Answers From the Lab” podcast on Mayo Clinic Laboratories Insights.

Kevin Ritchart

Kevin Ritchart is a copywriter at Mayo Clinic Laboratories. He joined the company in 2022 and has nearly 10 years of experience writing for healthcare and scientific audiences.